Evidence map›Paper›PMID 36321792›Full record

ArticleOncology reports2022

MicroRNA profiling of paediatric AML with

Pier Paolo Leoncini, Patrizia Vitullo, Sofia Reddel, Valeria Tocco, Valeria Paganelli, Francesca Stocchi, Elena Mariggiò, Michele Massa, Giovanni Nigita, Dario Veneziano and 7 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 3 countries.

Pier Paolo LeonciniDepartment of Paediatric Haematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, I-00146 Rome, Italy.
Patrizia VitulloDepartment of Paediatric Haematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, I-00146 Rome, Italy.
Sofia ReddelDepartment of Paediatric Haematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, I-00146 Rome, Italy.
Valeria ToccoDepartment of Paediatric Haematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, I-00146 Rome, Italy.
Valeria PaganelliDepartment of Paediatric Haematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, I-00146 Rome, Italy.
Francesca StocchiDepartment of Paediatric Haematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, I-00146 Rome, Italy.
Elena MariggiòDepartment of Paediatric Haematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, I-00146 Rome, Italy.
Michele MassaDepartment of Maternal Infantile and Urological Sciences, Sapienza University of Rome, I-00161 Rome, Italy.
Giovanni NigitaDepartment of Cancer Biology and Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210-1239, USA.
Dario VenezianoDepartment of Cancer Biology and Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210-1239, USA.
Paolo FaddaGenomics Shared Resource, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210-1239, USA.
Mario ScarpaDepartment of Biomedical Research, Urology Research Laboratory, University of Bern, CH-3008 Bern, Switzerland.
Martina PigazziDepartment of Women's and Children's Health (SDB), Hematology-Oncology Laboratory, University of Padova, I-35128 Padova, Italy.
Alice BertainaDepartment of Paediatric Haematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, I-00146 Rome, Italy.
Rossella RotaDepartment of Paediatric Haematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, I-00146 Rome, Italy.
Daria PagliaraDepartment of Paediatric Haematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, I-00146 Rome, Italy.
Pietro MerliDepartment of Paediatric Haematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, I-00146 Rome, Italy.
Bambino Gesù Children's Hospital · ITThe Ohio State University · USBern University of Applied Sciences · CHSapienza University of Rome · ITUniversity of Padua · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Novel therapeutic strategies are needed for paediatric patients affected by Acute Myeloid Leukaemia (AML), particularly for those at high-risk for relapse. MicroRNAs (miRs) have been extensively studied as biomarkers in cancer and haematological disorders, and their expression has been correlated to the presence of recurrent molecular abnormalities, expression of oncogenes, as well as to prognosis/clinical outcome. In the present study, expression signatures of different miRs related both to presence of myeloid/lymphoid or mixed-lineage leukaemia 1 and Fms like tyrosine kinase 3 internal tandem duplications rearrangements and to the clinical outcome of paediatric patients with AML were identified. Notably, miR-221-3p and miR-222-3p resulted as a possible relapse-risk related miR. Thus, miR-221-3p and miR-222-3p expression modulation was investigated by using a Bromodomain‑containing protein 4 (BRD4) inhibitor (JQ1) and a natural compound that acts as histone acetyl transferase inhibitor (curcumin), alone or in association, in order to decrease acetylation of histone tails and potentiate the effect of BRD4 inhibition. JQ1 modulates miR-221-3p and miR-222-3p expression in AML with a synergic effect when associated with curcumin. Moreover, changes were observed in the expression of

Indexed as

CurcuminLeukemia, Myeloid, AcuteMicroRNAsApoptosisBromodomain Containing ProteinsCell Cycle ProteinsChildHistonesHumansNeoplasm Recurrence, LocalNuclear ProteinsTranscription FactorsBRD4 protein, humanBromodomain Containing ProteinsCell Cycle ProteinsCurcuminHistonesMicroRNAsMIR221, humanMIR222, humanNuclear ProteinsTranscription Factorsacute myelogenous leukaemiabiomarkerschildrenepigenetic drugsmicroRNAs

Identifiers

PMID36321792
PMCPMC9647495
OpenAlexW4307868655

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.